Ocular adverse effects of checkpoint inhibitors and targeted therapy in cancer patients: A comparison with conventional chemotherapy
Indian Journal of Medical Research · 12.11.2026 · 1-8
DOI: 10.25259/ijmr_1746_2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical Research, online erschienen am 12.11.2026. Verfasst von Niranjana J. und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background and objectives With targeted therapy and immune checkpoint inhibitor therapies effectively extending cancer survival, patients experience various unique and sometimes dangerous adverse effects (AE), including ocular side effects. We conducted this study to compare the prevalence and clinical characteristics of various ocular AEs due to targeted therapy and immune checkpoint inhibitors vs. conventional chemotherapy agents.
Methods
In this prospective comparative cohort study, 130 patients with systemic malignancies on active drug treatment were categorised into cases (80 on targeted therapy or immune checkpoint inhibitors) and controls (50 on conventional chemotherapy). Detailed history was obtained, and complete ocular examinations were performed for all subjects, supplemented with dry eye evaluation tests and ultrawide-field retinal imaging. Ocular ultrasonography, fundus fluorescein angiography, and optical coherence tomography were undertaken whenever indicated.
Results
Anterior segment AEs in cases vs. controls respectively were: dry eye in 36.25% (n=29) versus 22% (n=11), superficial punctate keratitis in 1 vs. 3, and sterile corneal melt in 1 vs. nil. Adnexal AEs in cases included cilia incarnata, dermatochalasis, ptosis, periocular hyperpigmentation and hypertrichosis, in one patient each. Controls showed poliosis, madarosis, and hypotrichosis in 5 patients, and a single patient each of dermatochalasis and trichiasis. Uveo-retinal AEs in cases included uveitis (n=2), macular drusenoid deposits (n=5), CSR-like change (central serous retinopathy-like) (n=1), vascular sheathing (n=1), sclerosed vessels (n=2), and dasatinib-induced CMV retinitis (n=1). Controls showed atypical drusenoid deposits (n=1), non-specific pigmentary changes (n=3), and non-specific haemorrhages (n=1). Tumour-related complications included bilateral leukemic choroidal infiltrates and exudative retinal detachment. Interpretation and conclusions Dry eye and uveo-retinal changes seem to occur more frequently with novel cancer therapy compared to conventional chemotherapy. Patients on newer therapeutic drugs appear to be at risk of serious AEs such as sterile corneal melt, uveitis, and CMV retinitis. Early ocular screening of symptomatic patients on targeted therapy and immune checkpoint inhibitors is recommended.
Zitieren
APA
J., N., Venkatesh, P., Mallik, P. S., Batra, A., Agarwal, T., Vanathi, M., & Azad, S. V. (2026). Ocular adverse effects of checkpoint inhibitors and targeted therapy in cancer patients: A comparison with conventional chemotherapy. Indian Journal of Medical Research, 0, 1-8. https://doi.org/10.25259/ijmr_1746_2026
Vancouver
J. N, Venkatesh P, Mallik PS, Batra A, Agarwal T, Vanathi M, et al. Ocular adverse effects of checkpoint inhibitors and targeted therapy in cancer patients: A comparison with conventional chemotherapy. Indian Journal of Medical Research. 2026;0:1-8. doi:10.25259/ijmr_1746_2026
BibTeX
@article{J2026,
author = {J., Niranjana and Venkatesh, Pradeep and Mallik, Prabhat Singh and Batra, Atul and Agarwal, Tushar and Vanathi, Murugesan and Azad, Shorya Vardhan},
title = {Ocular adverse effects of checkpoint inhibitors and targeted therapy in cancer patients: A comparison with conventional chemotherapy},
journal = {Indian Journal of Medical Research},
year = {2026},
volume = {0},
pages = {1--8},
doi = {10.25259/ijmr_1746_2026}
}
EUVIMED